Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer
PeerJ · 2025
DOI: 10.7717/peerj.19968 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Lijin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Adenoma, DNA Methylation, Feces. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, China.
Abstract (Originalsprache)
Background
To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer.
Methods
The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specific quantitative polymerase chain reaction (PCR).
Results
In tissue samples, the NEUROG1 methylation detection rates were 36% for CRC, 24% for NAA, and 88% for AA. In stool samples, the NEUROG1 methylation detection had a sensitivity of 63.46% for CRC with a positive predictive value (PPV) of 85.94%. The overall diagnostic specificity of the test for the NAA and the healthy control was 76.32%, with a negative predictive value (NPV) of 40.28%.
Conclusion
NEUROG1 methylation detection can potentially be used in the CRC and AA screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, the Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Gastroenterology, Fujian Provincial Hospital, Fuzhou, Fujian, China.
- Department of Gastroenterology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
- Department of Pathology, Fujian Provincial Hospital, Fuzhou, Fujian, China.
- Jiangsu Microdiag Biomedical Technology Co., LTD, Suzhou, Jiangsu, China.
Förderung
- Natural Science Foundation of Fujian Province, China
Zitieren
APA
Zhang, L., Lin, A., Lin, J., Chen, J., Chen, M., Yu, X., Wu, Y., Wang, T., Lu, Y., Ba, Z., Cheng, X., Zhang, T., & Chen, M. (2025). Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer. PeerJ. https://doi.org/10.7717/peerj.19968
Vancouver
Zhang L, Lin A, Lin J, Chen J, Chen M, Yu X, et al. Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer. PeerJ. 2025. doi:10.7717/peerj.19968
BibTeX
@article{Zhang2025,
author = {Zhang, Lijin and Lin, Aiping and Lin, Jie and Chen, Juan and Chen, Mengshi and Yu, Xunbin and Wu, Yijuan and Wang, Tao and Lu, Yan and Ba, Zhaofen and Cheng, Xiaowei and Zhang, Tiantian and Chen, Minghong},
title = {Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19968}
}
EUVIMED